ArticleProceedings of the National Academy of Sciences of the United States of America1996
Insulin-secreting non-islet cells are resistant to autoimmune destruction.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 73 citations in OpenAlex.
- Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.Cells · 2022Review
- Regenerative medicine and cell-based approaches to restore pancreatic function.Nature reviews. Gastroenterology & hepatology · 2017Review
- Engineered insulin secretion from neuroendocrine cells isolated from human thyroid.World journal of surgery · 2014Article
- Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells.Biotechnology and bioengineering · 2012Article
- Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoter.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- A cell-based approach for diabetes treatment using engineered non-beta cells.Journal of diabetes science and technology · 2009Article
- Insulin expressing hepatocytes not destroyed in transgenic NOD mice.Journal of autoimmune diseases · 2004Article
- Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor.Gene therapy · 2003Article
- Gene- and cell-based therapeutics for type I diabetes mellitus.Gene therapy · 2003Review
- Adenoviral vector-mediated insulin gene transfer in the mouse pancreas corrects streptozotocin-induced hyperglycemia.Gene therapy · 2001Article
- Expression of the human insulin gene in the gastric G cells of transgenic mice.Transgenic research · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transgenic nonobese diabetic mice were created in which insulin expression was targeted to proopiomelanocortin-expressing pituitary cells. Proopiomelanocortin-expressing intermediate lobe pituitary cells efficiently secrete fully processed, mature insulin via a regulated secretory pathway, similar to islet beta cells. However, in contrast to the insulin-producing islet beta cells, the insulin-producing intermediate lobe pituitaries are not targeted or destroyed by cells of the immune system. Transplantation of the transgenic intermediate lobe tissues into diabetic nonobese diabetic mice resulted in the restoration of near-normoglycemia and the reversal of diabetic symptoms. The absence of autoimmunity in intermediate lobe pituitary cells engineered to secrete bona fide insulin raises the potential of these cell types for beta-cell replacement therapy for the treatment of insulin-dependent diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.